Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation

Journal of Leukocyte Biology

Volumn 94, Issue 4, 2013, Pages 563-573

  Yanaba, Koichi ^a   Kamata, Masahiro ^a   Ishiura, Nobuko ^b   Shibata, Sayaka ^a   Asano, Yoshihide ^a   Tada, Yayoi ^a   Sugaya, Makoto ^a   Kadono, Takafumi ^a   Tedder, Thomas F ^c   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B10 cells; Cytokines; IL 10

Indexed keywords

GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; IONOMYCIN; MONENSIN;

ACANTHOSIS; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTACT ALLERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATITIS; DISEASE SEVERITY; HYPERKERATOSIS; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PARAKERATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REGULATORY T LYMPHOCYTE;

B10 CELLS; CYTOKINES; IL-10;

AMINOQUINOLINES; ANIMALS; ANTIGENS, CD19; ANTIGENS, CD1D; ANTIGENS, CD5; B-LYMPHOCYTES, REGULATORY; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; LYMPH NODES; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; PHENOTYPE; PSORIASIS; RNA, MESSENGER; SKIN; SPLEEN;

EID: 84884866946     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.1112562     Document Type: Article

References (39)

1. Nestle, F. O., Kaplan, D. H., Barker, J. (2009) Psoriasis. N. Engl. J. Med. 361, 496-09.
2. Lowes, M. A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L. C., Haider, A. S., Bowman, E. P., Krueger, J. G. (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128, 1207-1211.
3. Schon, M. P., Ruzicka, T. (2001) Psoriasis: the plot thickens. Nat. Immunol. 2, 91.
4. Gilliet, M., Conrad, C., Geiges, M., Cozzio, A., Thurlimann, W., Burg, G., Nestle, F. O., Dummer, R. (2004) Psoriasis triggered by Toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch. Dermatol. 140, 1490-1495.
5. Patel, U., Mark, N. M., Machler, B. C., Levine, V. J. (2011) Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br. J. Dermatol. 164, 670-672.
6. Schon, M. P., Schon, M. (2007) Imiquimod: mode of action. Br. J. Dermatol. 157 (Suppl. 2), 8-13.
7. Van der Fits, L., Mourits, S., Voerman, J. S., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A. M., Florencia, E., Prens, E. P., Lubberts, E. (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182, 5836-5845.
8. + T cell activation in mice. Proc. Natl. Acad. Sci. USA 104, 20882-20887.
9. Xiu, Y., Wong, C. P., Hamaguchi, Y., Wang, Y., Pop, S., Tisch, R. M., Tedder, T. F. (2008) B lymphocytes depletion by CD20 monoclonal antibody prevents diabetes in NOD mice despite isotype-specific differences in FcγR effector functions. J. Immunol. 180, 2863-2875.
10. + T cells to protein antigens in vivo. J. Immunol. 155, 3734-3741.
11. Harris, D. P., Haynes, L., Sayles, P. C., Duso, D. K., Eaton, S. M., Lepak, N. M., Johnson, L. L., Swain, S. L., Lund, F. E. (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 1, 475-482.
12. Linton, P. J., Bautista, B., Biederman, E., Bradley, E. S., Harbertson, J., Kondrack, R. M., Padrick, R. C., Bradley, L. M. (2003) Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J. Exp. Med. 197, 875-883.
13. Bouaziz, J. D., Yanaba, K., Tedder, T. F. (2008) Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 224, 201-214.
14. + phenotype controls T cell-dependent inflammatory responses. Immunity 28, 639-650.
15. Matsushita, T., Yanaba, K., Bouaziz, J. D., Fujimoto, M., Tedder, T. F. (2008) Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420-3430.
16. Yanaba, K., Yoshizaki, A., Asano, Y., Kadono, T., Tedder, T. F., Sato, S. (2011) IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am. J. Pathol. 178, 735-743.
17. Yanaba, K., Bouaziz, J. D., Matsushita, T., Tsubata, T., Tedder, T. F. (2009) The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol. 182, 7459-7472.
18. Asadullah, K., Sterry, W., Stephanek, K., Jasulaitis, D., Leupold, M., Audring, H., Volk, H. D., Docke, W. D. (1998) IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J. Clin. Invest. 101, 783-794.
19. Weiss, E., Mamelak, A. J., La Morgia, S., Wang, B., Feliciani, C., Tulli, A., Sauder, D. N. (2004) The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases. J. Am. Acad. Dermatol. 50, 657-675.
20. Dass, S., Vital, E. M., Emery, P. (2007) Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 56, 2715-2718.
21. Mielke, F., Schneider-Obermeyer, J., Dorner, T. (2008) Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann. Rheum. Dis. 67, 1056-1057.
22. Engel, P., Zhou, L-J., Ord, D. C., Sato, S., Koller, B., Tedder, T. F. (1995) Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3, 39-50.
23. Sato, S., Ono, N., Steeber, D. A., Pisetsky, D. S., Tedder, T. F. (1996) CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157, 4371-4378.
24. Ishizaki, M., Akimoto, T., Muromoto, R., Yokoyama, M., Ohshiro, Y., Sekine, Y., Maeda, H., Shimoda, K., Oritani, K., Matsuda, T. (2011) Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J. Immunol. 187, 181-189.
25. Matsushita, T., Horikawa, M., Iwata, Y., Tedder, T. F. (2010) Regulatory B cells (B10 cells) and regulatory T cells have indepedent roles in controling experimental autoimmune encephalomyelitis initiation and latephase immunopathogenesis. J. Immunol. 185, 2240-2252.
26. Yanaba, K., Bouaziz, J. D., Matsushita, T., Magro, C. M., St Clair, E. W., Tedder, T. F. (2008) B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 223, 284-299.
27. Hasegawa, M., Hamaguchi, Y., Yanaba, K., Bouaziz, J-D., Uchida, J., Fujimoto, M., Matsushita, T., Matsushita, Y., Horikawa, M., Komura, K., Takehara, K., Sato, S., Tedder, T. F. (2006) B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am. J. Pathol. 169, 954-966.
28. Yanaba, K., Hamaguchi, Y., Venturi, G. M., Steeber, D. A., St. Clair, E. W., Tedder, T. F. (2007) B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J. Immunol. 179, 1369-1380.
29. Cohen, J. D. (2008) Successful treatment of psoriatic arthritis with rituximab. Ann. Rheum. Dis. 67, 1647-1648.
30. Asadullah, K., Sterry, W., Volk, H. D. (2003) Interleukin-10 therapy-review of a new approach. Pharmacol. Rev. 55, 241-269.
31. Borghi, A., Fogli, E., Stignani, M., Melchiorri, L., Altieri, E., Baricordi, O., Rizzo, R., Virgili, A. (2008) Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease. Arch. Dermatol. Res. 300, 551-559.
32. Takahashi, H., Tsuji, H., Hashimoto, Y., Ishida-Yamamoto, A., Iizuka, H. (2010) Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin. Exp. Dermatol. 35, 645-649.
33. Asadullah, K., Docke, W. D., Ebeling, M., Friedrich, M., Belbe, G., Audring, H., Volk, H. D., Sterry, W. (1999) Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch. Dermatol. 135, 187-192.
34. Reich, K., Bruck, M., Grafe, A., Vente, C., Neumann, C., Garbe, C. (1998) Treatment of psoriasis with interleukin-10. J. Invest. Dermatol. 111, 1235-1236.
35. Kimball, A. B., Kawamura, T., Tejura, K., Boss, C., Hancox, A. R., Vogel, J. C., Steinberg, S. M., Turner, M. L., Blauvelt, A. (2002) Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch. Dermatol. 138, 1341-1346.
36. Van Deventer, S. J., Elson, C. O., Fedorak, R. N. (1997) Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 113, 383-389.
37. Iwata, Y., Matsushita, T., Horikawa, M., Dilillo, D. J., Yanaba, K., Venturi, G. M., Szabolcs, P. M., Bernstein, S. H., Magro, C. M., Williams, A. D., Hall, R. P., St Clair, E. W., Tedder, T. F. (2011) Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117, 530-541.
38. hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32, 129-140.
39. + T-cell activation in vitro. Eur. J. Immunol. 40, 2686-2691.